Strategic Partners (CPSE:STRAP) - Prezzo delle azioni, notizie e analisi

STRAP Panoramica delle azioni

Strategic Partners A/S non ha operazioni significative.

STRAP analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 42.7% all'anno negli ultimi 5 anni

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( DKK0 )

Non ha una capitalizzazione di mercato significativa ( DKK40M )

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Gli azionisti sono stati diluiti nell'ultimo anno

Strategic Partners A/S Concorrenti

BioPorto

CPSE:BIOPOR

DKK 837.8m

Enzon Pharmaceuticals

OTCPK:ENZN

US$6.7m

TME Pharma

ENXTPA:ALTME

€6.2m

Cyclerion Therapeutics

NasdaqCM:CYCN

US$7.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Strategic Partners
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 948.20
Massimo di 52 settimane	DKK 1,525.00
Minimo di 52 settimane	DKK 407.00
Beta	0.079
1Variazione di 1 mese	-20.94%
Variazione a 3 mesi	14.91%
Variazione di 1 anno	6.30%
3Variazione a 3 anni	-96.45%
Variazione a 5 anni	-98.14%
Variazione dall'IPO	-98.81%

Notizie e aggiornamenti recenti

Recent updates

What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?

Mar 04

How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?

Nov 19

Rendimenti per gli azionisti

	STRAP	DK Biotechs	DK Mercato
7D	-15.3%	-1.9%	-2.8%
1Y	6.3%	7.2%	14.3%

Ritorno vs Industria: STRAP ha avuto una performance inferiore rispetto al Danish Biotechs che ha registrato un rendimento 7.2 % nell'ultimo anno.

Rendimento vs Mercato: STRAP ha avuto una performance inferiore al mercato Danish che ha registrato un rendimento 14.3 % nell'ultimo anno.

Volatilità dei prezzi

Is STRAP's price volatile compared to industry and market?
STRAP volatility
STRAP Average Weekly Movement	10.6%
Biotechs Industry Average Movement	7.7%
Market Average Movement	4.4%
10% most volatile stocks in DK Market	8.8%
10% least volatile stocks in DK Market	2.5%

Prezzo delle azioni stabile: Il prezzo delle azioni di STRAP è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 11% ) di STRAP è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Danish.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	1	Jakob Bendtsen	www.strategic-partners.dk

Strategic Partners A/S non ha operazioni significative. In precedenza era impegnata nello sviluppo di terapie per il trattamento di malattie rare neurodegenerative. La società era precedentemente nota come Orphazyme A/S e ha cambiato nome in Strategic Partners A/S nell'ottobre 2024.

Strategic Partners A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Strategic Partners con la sua capitalizzazione di mercato?
STRAP statistiche fondamentali
Capitalizzazione di mercato	DKK 39.55m
Guadagni(TTM)	-DKK 11.42m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-3.5x

Rapporto P/E

STRAP è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
STRAP Conto economico (TTM)
Ricavi	DKK 0
Costo del fatturato	DKK 0
Profitto lordo	DKK 0
Altre spese	DKK 11.42m
Guadagni	-DKK 11.42m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-273.69
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato STRAP nel lungo periodo?

Vedi performance storica e confronto

STRAP Panoramica delle azioni

Premi

Analisi del rischio

Strategic Partners A/S Concorrenti

CPSE:BIOPOR

DKK 837.8m

OTCPK:ENZN

US$6.7m

ENXTPA:ALTME

€6.2m

NasdaqCM:CYCN

US$7.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New minor risk - Shareholder dilution

New major risk - Share price stability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Recent updates

New minor risk - Shareholder dilution

New major risk - Share price stability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Price target decreased to kr.81.00

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Consensus revenue estimates fall to kr.95.0m

Price target increased to kr.127

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Price target lowered to kr.135

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: kr.78.30

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: kr.56.30

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: kr.66.00

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low: kr.80.60

New 90-day low - kr.87.00

Rendimenti per gli azionisti